FDA Approves New Companion Diagnostics for Prostate Cancer Treatment
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read MorePosted by CLP Edit Staff | Jun 1, 2026 | Prostate |
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read MorePosted by CLP Edit Staff | Jun 1, 2026 | Cancer, Diagnostic Technologies, Molecular Diagnostics |
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read MorePosted by CLP Edit Staff | May 29, 2026 | Compliance, Lung Cancer |
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read MorePosted by CLP Edit Staff | May 22, 2026 | Lung Cancer, Molecular Diagnostics |
The tissue-based test identifies patients with MET exon 14 skipping alterations eligible for treatment with tepotinib.
Read MorePosted by CLP Edit Staff | May 18, 2026 | Cancer, Company News, Molecular Diagnostics |
CMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Read More